Vorasidenib

CHEMBL4279047 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

414.7 g/mol

LogP

5.3

Phase

4

Vorasidenib is a dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (mIDH1 and mIDH2) that blocks the neomorphic enzymatic activity responsible for producing the oncometabolite 2-hydroxyglutarate (2-HG) in IDH-mutant glioma cells. 2-HG accumulation causes epigenetic dysregulation through inhibition of alpha-ketoglutarate-dependent dioxygenases, leading to differentiation arrest in neural progenitor cells. It is approved for the treatment of grade 2 IDH-mutant glioma in adults, representing the first targeted therapy for this brain tumor subtype.

Berat Molekul

414,7400 g/mol

LogP

5,30

TPSA

75,60 Å²

Lipinski RO5

Gagal

Area Terapeutik

Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F

InChI

InChI=1S/C14H13ClF6N6/c1-6(13(16,17)18)22-11-25-10(8-4-3-5-9(15)24-8)26-12(27-11)23-7(2)14(19,20)21/h3-7H,1-2H3,(H2,22,23,25,26,27)/t6-,7-/m1/s1

Molecular Formula

C14H13ClF6N6

HBD / HBA

2 / 12

Ikatan yang Dapat Dirotasi

5

Atom Berat

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Vorasidenib is a dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (mIDH1 and mIDH2) that blocks the neomorphic enzymatic activity responsible for producing the oncometabolite 2-hydroxyglutarate (2-HG) in IDH-mutant glioma cells. 2-HG accumulation causes epigenetic dysregulation through inhibition of alpha-ketoglutarate-dependent dioxygenases, leading to differentiation arrest in neural progenitor cells. It is approved for the treatment of grade 2 IDH-mutant glioma in adults, representing the first targeted therapy for this brain tumor subtype.

Yes, Vorasidenib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4279047. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 117817422. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Mencari informasi yang ramah bagi pasien?

Vorasidenib di PillFYI

Struktur

Data Cepat

Rumus: C14H13ClF6N6
Sinonim: 1

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.